Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Immunol Methods ; 475: 112631, 2019 12.
Artigo em Inglês | MEDLINE | ID: mdl-31306640

RESUMO

The rise in the analytical speed of mutiparameter flow cytometers made possible by the introduction of digital instruments, has brought up the possibility to manage progressively higher number of parameters simultaneously on significantly greater numbers of individual cells. This has led to an exponential increase in the complexity and volume of flow cytometry data generated about cells present in individual samples evaluated in a single measurement. This increase demands for new developments in flow cytometry data analysis, graphical representation, and visualization and interpretation tools to address the new big data challenges, i.e. processing data files of ≥10-25 parameters per cell in samples with >5-10 million cells (= up to 250 million data points per cell sample) obtained in a few minutes. Here, we present a comprehensive review of some of the tools developed by the EuroFlow consortium for processing flow cytometric big data files in diagnostic laboratories, particularly focused on automated EuroFlow approaches for: i) identification of all cell populations coexisting in a sample (automated gating); ii) smart classification of aberrant cell populations in routine diagnostics; iii) automated reporting; together with iv) new tools developed to visualize n-dimensional data in 2-dimensional plots to support expert-guided automated data analysis. The concept of using reference data bases implemented into software programs, in combination with multivariate statistical analysis pioneered by EuroFlow, provides an innovative, highly efficient and fast approach for diagnostic screening, classification and monitoring of patients with distinct hematological and immune disorders, as well as other diseases.


Assuntos
Big Data , Conjuntos de Dados como Assunto , Citometria de Fluxo/métodos , Imunofenotipagem/métodos , Humanos
2.
Leukemia ; 32(4): 874-881, 2018 04.
Artigo em Inglês | MEDLINE | ID: mdl-29089646

RESUMO

Precise classification of acute leukemia (AL) is crucial for adequate treatment. EuroFlow has previously designed an AL orientation tube (ALOT) to guide towards the relevant classification panel (T-cell acute lymphoblastic leukemia (T-ALL), B-cell precursor (BCP)-ALL and/or acute myeloid leukemia (AML)) and final diagnosis. Now we built a reference database with 656 typical AL samples (145 T-ALL, 377 BCP-ALL, 134 AML), processed and analyzed via standardized protocols. Using principal component analysis (PCA)-based plots and automated classification algorithms for direct comparison of single-cells from individual patients against the database, another 783 cases were subsequently evaluated. Depending on the database-guided results, patients were categorized as: (i) typical T, B or Myeloid without or; (ii) with a transitional component to another lineage; (iii) atypical; or (iv) mixed-lineage. Using this automated algorithm, in 781/783 cases (99.7%) the right panel was selected, and data comparable to the final WHO-diagnosis was already provided in >93% of cases (85% T-ALL, 97% BCP-ALL, 95% AML and 87% mixed-phenotype AL patients), even without data on the full-characterization panels. Our results show that database-guided analysis facilitates standardized interpretation of ALOT results and allows accurate selection of the relevant classification panels, hence providing a solid basis for designing future WHO AL classifications.


Assuntos
Leucemia Mieloide Aguda/patologia , Doença Aguda , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Feminino , Humanos , Imunofenotipagem/métodos , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Leucemia-Linfoma Linfoblástico de Células Precursoras/patologia , Adulto Jovem
3.
Leukemia ; 31(10): 2094-2103, 2017 10.
Artigo em Inglês | MEDLINE | ID: mdl-28104919

RESUMO

Flow cytometry has become a highly valuable method to monitor minimal residual disease (MRD) and evaluate the depth of complete response (CR) in bone marrow (BM) of multiple myeloma (MM) after therapy. However, current flow-MRD has lower sensitivity than molecular methods and lacks standardization. Here we report on a novel next generation flow (NGF) approach for highly sensitive and standardized MRD detection in MM. An optimized 2-tube 8-color antibody panel was constructed in five cycles of design-evaluation-redesign. In addition, a bulk-lysis procedure was established for acquisition of ⩾107 cells/sample, and novel software tools were constructed for automatic plasma cell gating. Multicenter evaluation of 110 follow-up BM from MM patients in very good partial response (VGPR) or CR showed a higher sensitivity for NGF-MRD vs conventional 8-color flow-MRD -MRD-positive rate of 47 vs 34% (P=0.003)-. Thus, 25% of patients classified as MRD-negative by conventional 8-color flow were MRD-positive by NGF, translating into a significantly longer progression-free survival for MRD-negative vs MRD-positive CR patients by NGF (75% progression-free survival not reached vs 7 months; P=0.02). This study establishes EuroFlow-based NGF as a highly sensitive, fully standardized approach for MRD detection in MM which overcomes the major limitations of conventional flow-MRD methods and is ready for implementation in routine diagnostics.


Assuntos
Citometria de Fluxo/métodos , Imunofenotipagem/métodos , Mieloma Múltiplo/diagnóstico , Plasmócitos/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Especificidade de Anticorpos , Contagem de Células , Desenho de Equipamento , Feminino , Citometria de Fluxo/instrumentação , Humanos , Imunofenotipagem/instrumentação , Masculino , Pessoa de Meia-Idade , Mieloma Múltiplo/tratamento farmacológico , Mieloma Múltiplo/patologia , Neoplasia Residual , Sensibilidade e Especificidade , Software , Manejo de Espécimes , Resultado do Tratamento
4.
Artigo em Romano | MEDLINE | ID: mdl-217065

RESUMO

The present work demonstrates the high overall efficiency of the present regimes in the treatment of tuberculosis (97%), provided the rules and indications are strictly complied with. The duration of the medical sick leave influences the regularity with which the treatment is applied. Many of the younger patients frequently accept to resume work at an earlier date. Earlier work resumption under present conditions should be had in view since it obviates the major drawbacks in the treatment of tuberculosis--socio-occupational disadaptation of the patients.


Assuntos
Antituberculosos/uso terapêutico , Tuberculose Pulmonar/tratamento farmacológico , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de Tempo , Tuberculose Pulmonar/reabilitação
5.
Artigo em Romano | MEDLINE | ID: mdl-171749

RESUMO

Three detections, carried out over a period of two years gave the following results: a high rate was obtained in the first one while the following two gave lower rates, in parallel with a decrease of the overall incidence through pulmonary tuberculosis from 326.70/0000 in 1968 to 1440/0000 in 1973. The cases were recently detected, during the last two investigations, which allowed for a wider application of the ambulatory treatment, a fact that compensated from the financial view point the cost of radiophotographic investigations. The authors suggest the maintenance of integral detection, with the same periodicity in the rural environment.


Assuntos
Radiografia Pulmonar de Massa , Tuberculose Pulmonar/epidemiologia , Humanos , Romênia , População Rural
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA